211 related articles for article (PubMed ID: 36533396)
1. Ulotaront: a TAAR1/5-HT1A agonist in clinical development for the treatment of schizophrenia.
Højlund M; Correll CU
Expert Opin Investig Drugs; 2022 Dec; 31(12):1279-1290. PubMed ID: 36533396
[TBL] [Abstract][Full Text] [Related]
2. Ulotaront: review of preliminary evidence for the efficacy and safety of a TAAR1 agonist in schizophrenia.
Achtyes ED; Hopkins SC; Dedic N; Dworak H; Zeni C; Koblan K
Eur Arch Psychiatry Clin Neurosci; 2023 Oct; 273(7):1543-1556. PubMed ID: 37165101
[TBL] [Abstract][Full Text] [Related]
3. Ulotaront, a novel TAAR1 agonist with 5-HT1A agonist activity, lacks abuse liability and attenuates cocaine cue-induced relapse in rats.
Synan C; Bowen C; Heal DJ; Froger-Colléaux C; Beardsley PM; Dedic N; Hopkins SC; Campbell U; Koblan KS
Drug Alcohol Depend; 2022 Feb; 231():109261. PubMed ID: 35033729
[TBL] [Abstract][Full Text] [Related]
4. Efficacy, safety, and tolerability of ulotaront (SEP-363856, a trace amine-associated receptor 1 agonist) for the treatment of schizophrenia and other mental disorders: a systematic review of preclinical and clinical trials.
Le GH; Gillissie ES; Rhee TG; Cao B; Alnefeesi Y; Guo Z; Di Vincenzo JD; Jawad MY; March AM; Ramachandra R; Lui LMW; McIntyre RS
Expert Opin Investig Drugs; 2023 May; 32(5):401-415. PubMed ID: 37096491
[TBL] [Abstract][Full Text] [Related]
5. In Vitro Comparison of Ulotaront (SEP-363856) and Ralmitaront (RO6889450): Two TAAR1 Agonist Candidate Antipsychotics.
Ågren R; Betari N; Saarinen M; Zeberg H; Svenningsson P; Sahlholm K
Int J Neuropsychopharmacol; 2023 Sep; 26(9):599-606. PubMed ID: 37549917
[TBL] [Abstract][Full Text] [Related]
6. Unlocking the Therapeutic Potential of Ulotaront as a Trace Amine-Associated Receptor 1 Agonist for Neuropsychiatric Disorders.
Kuvarzin SR; Sukhanov I; Onokhin K; Zakharov K; Gainetdinov RR
Biomedicines; 2023 Jul; 11(7):. PubMed ID: 37509616
[TBL] [Abstract][Full Text] [Related]
7. [An antipsychotic without dopamine receptor blockade?].
Spoelstra SK; Bruggeman R; Knegtering H
Tijdschr Psychiatr; 2021; 63(11):804-809. PubMed ID: 34851520
[TBL] [Abstract][Full Text] [Related]
8. Population pharmacokinetic analysis of ulotaront in subjects with schizophrenia.
Galluppi GR; Polhamus DG; Fisher JM; Hopkins SC; Koblan KS
CPT Pharmacometrics Syst Pharmacol; 2021 Oct; 10(10):1245-1254. PubMed ID: 34292664
[TBL] [Abstract][Full Text] [Related]
9. TAAR1 agonist ulotaront delays gastric emptying of solids in patients with schizophrenia and concurrent metabolic syndrome with prediabetes.
Milanović S; Dedic N; Lew R; Burton D; Koblan KS; Camilleri M; Hopkins SC
Diabetes Obes Metab; 2024 Jun; 26(6):2466-2475. PubMed ID: 38533552
[TBL] [Abstract][Full Text] [Related]
10. A Non-D2-Receptor-Binding Drug for the Treatment of Schizophrenia.
Koblan KS; Kent J; Hopkins SC; Krystal JH; Cheng H; Goldman R; Loebel A
N Engl J Med; 2020 Apr; 382(16):1497-1506. PubMed ID: 32294346
[TBL] [Abstract][Full Text] [Related]
11. Therapeutic Potential of TAAR1 Agonists in Schizophrenia: Evidence from Preclinical Models and Clinical Studies.
Dedic N; Dworak H; Zeni C; Rutigliano G; Howes OD
Int J Mol Sci; 2021 Dec; 22(24):. PubMed ID: 34947997
[TBL] [Abstract][Full Text] [Related]
12. A New Treatment Paradigm: Targeting Trace Amine-Associated Receptor 1 (TAAR1) in Schizophrenia.
Kane JM
J Clin Psychopharmacol; 2022 Sep-Oct 01; 42(5 Suppl 1):S1-S13. PubMed ID: 36099402
[TBL] [Abstract][Full Text] [Related]
13. SEP-363856, a Novel Psychotropic Agent with a Unique, Non-D
Dedic N; Jones PG; Hopkins SC; Lew R; Shao L; Campbell JE; Spear KL; Large TH; Campbell UC; Hanania T; Leahy E; Koblan KS
J Pharmacol Exp Ther; 2019 Oct; 371(1):1-14. PubMed ID: 31371483
[TBL] [Abstract][Full Text] [Related]
14. New and emerging treatments for schizophrenia: a narrative review of their pharmacology, efficacy and side effect profile relative to established antipsychotics.
Lobo MC; Whitehurst TS; Kaar SJ; Howes OD
Neurosci Biobehav Rev; 2022 Jan; 132():324-361. PubMed ID: 34838528
[TBL] [Abstract][Full Text] [Related]
15. Ulotaront: A TAAR1 Agonist for the Treatment of Schizophrenia.
Heffernan MLR; Herman LW; Brown S; Jones PG; Shao L; Hewitt MC; Campbell JE; Dedic N; Hopkins SC; Koblan KS; Xie L
ACS Med Chem Lett; 2022 Jan; 13(1):92-98. PubMed ID: 35047111
[TBL] [Abstract][Full Text] [Related]
16. Depicting Safety Profile of TAAR1 Agonist Ulotaront Relative to Reactions Anticipated for a Dopamine D2-Based Pharmacological Class in FAERS.
Hopkins SC; Ogirala A; Worden M; Koblan KS
Clin Drug Investig; 2021 Dec; 41(12):1067-1073. PubMed ID: 34751928
[TBL] [Abstract][Full Text] [Related]
17. In Vitro ADME and Preclinical Pharmacokinetics of Ulotaront, a TAAR1/5-HT
Xiao G; Chen YL; Dedic N; Xie L; Koblan KS; Galluppi GR
Pharm Res; 2022 May; 39(5):837-850. PubMed ID: 35484370
[TBL] [Abstract][Full Text] [Related]
18. TAAR1 agonist ulotaront modulates striatal and hippocampal glutamate function in a state-dependent manner.
Yang SM; Ghoshal A; Hubbard JM; Gackière F; Teyssié R; Neale SA; Hopkins SC; Koblan KS; Bristow LJ; Dedic N
Neuropsychopharmacology; 2024 Jun; 49(7):1091-1103. PubMed ID: 38110609
[TBL] [Abstract][Full Text] [Related]
19. Trace Amine-Associated Receptor 1 as a Target for the Development of New Antipsychotics: Current Status of Research and Future Directions.
Kantrowitz JT
CNS Drugs; 2021 Nov; 35(11):1153-1161. PubMed ID: 34655036
[TBL] [Abstract][Full Text] [Related]
20. Emerging Treatments in Schizophrenia.
Correll CU; Abi-Dargham A; Howes O
J Clin Psychiatry; 2022 Feb; 83(1):. PubMed ID: 35172048
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]